Editors' Notes
Hemolytic adverse events with immune globulin products: product factors and patient risks
Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012
The role of isoagglutinins in intravenous immunoglobulin–related hemolysis
Intravenous immune globulin–related hemolysis: comparing two different methods for case assessment
Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin
Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012
Pathogenesis and mechanisms of antibody-mediated hemolysis
Possible mechanisms for intravenous immunoglobulin–associated hemolysis: clues obtained from review of clinical case reports
The role of inflammation in intravenous immune globulin–mediated hemolysis
Anti-A and anti-B: what are they and where do they come from?
Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale
Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?
Intravenous immunoglobulin–related hemolysis in patients treated for Kawasaki disease
Donor screening reduces the isoagglutinin titer in immunoglobulin products
Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products
Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products
Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin
Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products
Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go?